STOCKWATCH
·
Medical Specialities
Quarterly ResultApr 30, 2026, 04:24 PM

ILMN Q1 Revenue +4.8% to $1.09B; EPS $1.15; $1.5B Buyback Authorized

AI Summary

Illumina reported strong Q1 2026 financial results with revenue increasing 4.8% to $1.09 billion and non-GAAP diluted EPS reaching $1.15. The company's Board of Directors also authorized a new $1.5 billion share repurchase program, adding to the existing capacity. Following the strong performance, Illumina raised its full-year 2026 revenue and non-GAAP EPS guidance.

Key Highlights

  • Board authorized a new $1.5 billion share repurchase program.
  • Q1 2026 revenue increased 4.8% to $1.09 billion.
  • Non-GAAP diluted EPS was $1.15, up from $0.97 in Q1 2025.
  • Non-GAAP operating margin reached 21.9% for Q1 2026.
  • Raised FY2026 revenue guidance to $4.52-$4.62 billion.
  • Raised FY2026 non-GAAP EPS guidance to $5.15-$5.30.
  • Free cash flow for Q1 2026 was $251 million.
ILMN
Medical Specialities
ILLUMINA, INC.

Price Impact